AROG Pharmaceuticals, LLC Announces Presentation of Data on the Activity of Crenolanib Against Mutant PDGFR at 47th American Society of Clinical Oncology Annual Meeting
May 19, 2011 AROG Pharmaceuticals, LLC (AROG) is pleased to announce the presentation of a study entitled The Effect Of Crenolanib (CP-868,596) On Phosphorylation Of The Imatinib-Resistant D842V PDGFRA Activating Mutation Associated With Advanced Gastrointestinal Stromal Tumors on 4 June 2011 during the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO). The abstract of the presentation (abstract #10012) is available on the ASCO meeting website, www.asco.org.
The data that will be presented at ASCO continue to support the unique activity of crenolanib against D842V, an activating mutation of PDGFRA that is found in a subset of patients with gastrointestinal stromal tumors (GISTs). GISTs with the PDGFRA D842V mutation are clinically resistant to treatment with the currently approved drugs including imatinib and sunitinib said Dr. Michael Heinrich (Portland VA Medical Center, OHSU Knight Cancer Institute), principal author of the study. Crenolanib could be a valuable treatment option for these patients if this activity is confirmed in the on-going clinical trial.
Presentation Details:
The Effect Of Crenolanib (CP-868,596) On Phosphorylation Of The Imatinib-Resistant D842V PDGFRA Activating Mutation Associated With Advanced Gastrointestinal Stromal Tumors
- – Dr. Michael Heinrich, Portland VA Medical Center, OHSU Knight Cancer Institute
- – Abstract No. 10012
- – Session: Sarcoma
- – Saturday, 4 June 2011
- – Poster presentation: 8:00am 12:00pm (McCormick Place E450a)
- – Poster discussion: 12:00pm 1:00pm (McCormick Place E354b)
About Crenolanib
Crenolanib is a potent and selective inhibitor of platelet derived growth factor receptors (PDGFR), particularly mutant PDGFRα. AROG is investigating the activity of crenolanib against various cancers including GISTs, gliomas, lung and ovarian cancers for tumors that have either amplification, over-expression or mutations of PDGFRα.
AROG is conducting a Phase II trial in GIST patients with the D842V mutation in the PDGFRA gene (NCT01243346; www.clinicaltrials.gov). In addition, AROG is also supporting a Phase II trial with crenolanib for the treatment of adult gliomas (NCT01229644; www.clinicaltrials.gov)
About AROG Pharmaceuticals, LLC
AROG is a private, oncology-focused biopharmaceutical company based in Dallas, TX. AROGs mission is to develop novel anticancer drugs for the treatment of rare cancers with significant unmet medical need. To learn more about AROG, please visit www.arogpharma.com